An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.

Authors

Carol Aghajanian

Memorial Sloan-Kettering Cancer Center, New York, NY

Carol Aghajanian , Stephanie V. Blank , Barbara Ann Goff , Patricia Lynn Judson , Lawrence R. Nycum , Mika A. Sovak , Jing Yi , Amreen Husain

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Real-life data: Women with recurrent platinum-sensitive ovarian cancer and BCARGEM treatment.

First Author: Frederique C. van der Scheun

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.

First Author: Jing Wang

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).

First Author: Shom Goel

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer.

First Author: Ignace Vergote